top of page
  • Active, not recruiting

NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)

Updated: Aug 27, 2022


MMRF CoMMpass Study

Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass)


MMRF CoMMpass Study

The primary objective of this observational study is to identify the molecular profiles and clinical characteristics that define subsets of myeloma patients during the course of the disease.


Understanding the molecular basis of cancer is a critical step toward devising the most effective treatment of the patient as an individual. The promise of molecular targeted therapeutics and personalized cancer care has been demonstrated in breast and lung cancer and chronic myeloid leukemia. However, similar examples of success in multiple myeloma have not been achieved despite extensive basic research as well as clinical advances. What is well understood is that myeloma is a heterogeneous disease with great genetic and epigenetic complexity.22, 23 Therefore, there remains a critical need to understand myeloma patient biology in the context of current patient care.24 The objective of this longitudinal study is to identify patient subgroups and phenotypes defined by molecular profiling and clinical features. These profiles will enable a better understanding of mechanisms of disease, drug response and patient relapse. Ultimately the study is intended to drive successful drug development and patient care in multiple myeloma.


Sponsor

Multiple Myeloma Research Foundation

MMRF


Collaborators:

Translational Genomics Research Institute

Spectrum Health Hospitals

Van Andel Research Institute


Information provided by (Responsible Party):

Multiple Myeloma Research Foundation

 

ClinicalTrials.gov Identifier: NCT01454297

A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship Between Patient Outcomes, Treatment Regimens and Molecular Profiles

First Posted: October 19, 2011

Click here for details on ClinicalTrials.gov

 

MMRF CoMMpass Study

CoMMpass Study


NCT03657251: MMRF CureCloud Research Initiative

NCT03657251: MMRF CureCloud Research Initiative

 

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma

Blood; 2018 Aug

Click here for details


Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Leukemia; 2018 Apr

Click here for details


Genomic landscape and chronological reconstruction of driver events in multiple myeloma

Nat Commun; 2019 Aug

Click here for details


Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study

Clin Lymphoma Myeloma Leuk;2019

Click here for details


Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.

Clin Cancer Res. 2021 Jun

Click here for details


Evolution and structure of clinically relevant gene fusions in multiple myeloma.

Nat Commun. 2020

Click here for details


High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Blood Cancer J. 2017

Click here for details


MMRFBiolinks: an R-package for integrating and analyzing MMRF-CoMMpass data

Brief Bioinform; 2021

Click here for details


NIH National Cancer Institute - Genomics Data Commons: The Multiple Myeloma Research Foundation (MMRF)

Click here for details


CoMMpass from the Multiple Myeloma Research Foundation

Registry of Open Data on AWS

Click here for details

 

OAB-018 From CARDAMON to CoMMpass: A mutational signature that predicts carfilzomib-specific outcomes in myeloma -Ieuan Walker


#IMS2022 - 19th International Myeloma Society Annual Meeting; August 25-27, 2022 - LA, California

IMS 2022 Abstract EBook

https://www.myelomasociety.org/


#IMS2022 - 19th International Myeloma Society Annual Meeting; Aug 25-27, LA California (themyelomaclinicaltrials.com)

 

- Multiple locations

-International Study

 

- Arizona: Mayo Clinic Arizona

- California: University of California San Francisco

- Georgia: Emory University Atlanta

- Illinois: University of Chicago

- Missouri: Washington University School of Medicine Saint Louis

- Minnesota: Mayo Clinic Rochester Minnesota

- New Jersey: Hackensack University Medical Center

- New York: Memorial Sloan-Kettering Cancer Center New York

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- New York: NYU Langone Medical Center New York

- North Carolina: Levine Cancer Institute Charlotte

- Tennessee: Sarah Cannon Research Institute Nashville

- Texas: UT Southwestern Medical Center Dallas

- Texas: Baylor University Medical Center Dallas

 

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Connecticut

United States, District of Columbia

United States, Florida

United States, Georgia

United States, Illinois

United States, Kansas

United States, Maryland

United States, Michigan

United States, Minnesota

United States, Mississippi

United States, Missouri

United States, Montana

United States, Nebraska

United States, New Hampshire

United States, New Jersey

United States, New York

United States, North Carolina

United States, Ohio

United States, Oregon

United States, Tennessee

United States, Texas

United States, Virginia

United States, Washington

United States, Wisconsin

Canada, Alberta

Canada, Ontario

Canada, Quebec

Europe

Spain




Posts Archive